Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Плейотропные эффекты статинов на современном этапе их изучения (фокус на аторвастатин). Часть I - Научно-практический журнал Cardioсоматика Том 3, №3 (2012)
Плейотропные эффекты статинов на современном этапе их изучения (фокус на аторвастатин). Часть I
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В статье подробно обсуждаются плейотропные эффекты статинов, в том числе имеющие социальное значение, например, роль статинов в быстром купировании острого коронарного синдрома (ОКС), предупреждении мерцательной аритмии и других нарушений ритма ОКС, в периоперативном периоде хирургических и инвазивных вмешательств. Представляется классификация плейотропных эффектов статинов по отдельным направлениям. Обсуждаются некоторые неясные вопросы механизмов действия плейотропных свойств статинов.
Ключевые слова: статины, плейотропные эффекты.
Key words: statins, pleiotropic effects.
Ключевые слова: статины, плейотропные эффекты.
________________________________________________
Key words: statins, pleiotropic effects.
Полный текст
Список литературы
1. Аронов Д.М. Каскад терапевтических эффектов статинов. Кардиология. 2004; с. 85–94.
2. Аронов Д.М. Лечение и профилактика атеросклероза. М.: Триада-Х, 2000.
3. Abetel G, Poget PN, Bonnabry JP. Hypotensive effect of an inhibitor of cholesterol synthesis (fluvastatin). A pilot study Schweiz Med Wochenschr 1998; 128 (7): 272–7.
4. Borghi C, Dormi A, Veronesi M et al. Use of lipid-lowering drugs and blood pressure control in patients with arterial hypertension. J Clin Hypertens 2002; 4 (4): 277–85.
5. Kanaki AL, Sarafidis PA, Georgianos PI et al. Low-dose atorvastatin reduces ambulatory blood pressure in patients with mild hypertension and hypercholesterolaemia: a double-blind, randomised, placebo-controlled study. J Hum Hypertens 2011; doi 10. 1038/jhh.2011.80 (Epud ahead of print).
6. Leibovitz E, Beniashvili M, Zimlichaman R et al. Treatment with amplodipine and atorvastatin have addivite effect in improvement of arterial compliance in hypertensive hyperlipidemie patients. Am J Hypertens 2003; 16 (9 Pt. 1): 715–8.
7. Kuklinska AM, Mroczko B, Musial WJ et al. Influence of atorvastatin on blood pressure control in treated hypertensive, normolipemic patients – An open, pilot study. Blood Press 2010; 19 (4): 260–6.
8. Чазова И.Е, Ратова Л.Г. Комбинированная терапия артериальной гипертонии. Медиа Медика, 2007.
9. Simons LA, Ortiz M, Calcino G. Persistence with a single pill versus two pills of amlodipine and atorvastatin: the Australian experience Med I Aust 2011; 1, 195 (3): 134–7.
10. Derosa G, Maffioli P. Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients 2010; 8 (6): 835–43.
11. Zamorano J, Erdine S, Pavia A et al. Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial 2011; 27 (4): 821–33.
12. Kawai H, Deguchi S, Yamashita T et al. Synergistic benefit of combined amlodipine plus atorvastatin on neuronal damage after stroke in Zucker metabolic rat 2011; 1368: 317–23.
13. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survial Study (4S). Lancet 1994, 344: 1383–9.
14. Heart Protection Study Collaborative Group MRS/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 23–4.
15. Schwartz GG, Olsson AG, Ezekowitz MD et al. Effects of Atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomised controlled trial. JAMA 2001; 285: 1711–8.
16. La Rosa JC, Grundy, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425–35.
17. Greisenegger S, Mullner M, Tentschert S et al. Effect of pretreatment with statins on the severity of acute ischemic cerebrovascular events. J Neurol Sci 2004; p. 5–10
18. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs 2004; 64 (Suppl. 2): 43–60.
19. Всероссийское научное общество кардиологов (ВНОК), Национальное общество по изучению атеросклероза (НОА), Российское общество кардиосоматической реабилитации и вторичной профилактики (РОСОКР). Заключение экспертов по оптимизации терапии статинами в клинической практике. Рациональная фармакотерапия в кардиологии. 2011; 7 (1): 107–9.
20. Takemoto M, Node K, Nakagami H et al Statins as antioxidant therapy for preventing cardiac myocyte hypertropty. J Clin Invest 2001; 108 (10): 1429–37.
21. Fonarow GC, Right RS, Spencer FA et al. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol 2005; 96: 611–6.
22. Fruchart JC, Duriez P. HMG CoA reductase inhibitors and PPAR-alpha activators: are their effects on high-density lipoprotein cholesterol and their pleiotropic effects clinically relevant in prevention trials? Curr Atheroscler Rep 2002; (6): 403–4.
23. Оkazaki S, Yokoyama T et al. Early statin treatment in patients with acute coronary syndrome demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event the ESTABLISH Study Circulation 2004; 110 (9): 1061–8.
24. Horne BD, Muhlestein JB, Carlquist JF et al. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. J Am Coll Cardiol 2000; 36 (6): 1774–80.
25. De Sutter J, Kazmierczak J, Fonteyne W et al. Factors determining long term outcomes and survival in patients with coronary artery disease and ventricular tachyarrhythmias: a single center experience. Pacing Clin Electrophysiol 2000; 23 (11 Pt. 2): 1947–52.
26. Lorenz H, Junger C, Seidl K et al. Do statin influence the prognostic impact of non- sustained ventricular tachycardia after ST-elevation myocardial infarction? Eur Heart J 2005; 26: 1078–85.
27. Patti G, Chello M, Candura D et al. Randomised Trial of Atorvastatin for Reduction of Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery. Circulation 2006; 114: 1455–6128.
28. Tang Q, Huang J, Qian H et al. Antiarrhythmic effect of atorvastatin on autoimmune myocarditis is mediated by improving myocardial repolarization. Life Sci 2007; 80 (7): 601–8.
29. Kumagai K, Nakashima H, Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibition in a canine sterile pericarditis model. Cardiovasc Research 2004, 62: 105–11.
30. Pasceri V, Patti G, Nusca A et al. Randomised Trial of Atorvastatin for Reduction of Myocardial Damage During Coronary Intervention. Circulation 2004; 110: 674–8.
31. Rikitake Y, Kawashima S et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterolfed rabbits Atherosclerosis 2001; 154 (1): 87–96.
32. Pehlivanidis AN, Athyros VG, Demitriadis DS et al. Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease. Atherosclerosis 2001; 157 (2): 463–9.
33.Young-Xu Y, Jabbour S et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003; 15, 92, 12: 1379–83.
2. Аронов Д.М. Лечение и профилактика атеросклероза. М.: Триада-Х, 2000.
3. Abetel G, Poget PN, Bonnabry JP. Hypotensive effect of an inhibitor of cholesterol synthesis (fluvastatin). A pilot study Schweiz Med Wochenschr 1998; 128 (7): 272–7.
4. Borghi C, Dormi A, Veronesi M et al. Use of lipid-lowering drugs and blood pressure control in patients with arterial hypertension. J Clin Hypertens 2002; 4 (4): 277–85.
5. Kanaki AL, Sarafidis PA, Georgianos PI et al. Low-dose atorvastatin reduces ambulatory blood pressure in patients with mild hypertension and hypercholesterolaemia: a double-blind, randomised, placebo-controlled study. J Hum Hypertens 2011; doi 10. 1038/jhh.2011.80 (Epud ahead of print).
6. Leibovitz E, Beniashvili M, Zimlichaman R et al. Treatment with amplodipine and atorvastatin have addivite effect in improvement of arterial compliance in hypertensive hyperlipidemie patients. Am J Hypertens 2003; 16 (9 Pt. 1): 715–8.
7. Kuklinska AM, Mroczko B, Musial WJ et al. Influence of atorvastatin on blood pressure control in treated hypertensive, normolipemic patients – An open, pilot study. Blood Press 2010; 19 (4): 260–6.
8. Чазова И.Е, Ратова Л.Г. Комбинированная терапия артериальной гипертонии. Медиа Медика, 2007.
9. Simons LA, Ortiz M, Calcino G. Persistence with a single pill versus two pills of amlodipine and atorvastatin: the Australian experience Med I Aust 2011; 1, 195 (3): 134–7.
10. Derosa G, Maffioli P. Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients 2010; 8 (6): 835–43.
11. Zamorano J, Erdine S, Pavia A et al. Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial 2011; 27 (4): 821–33.
12. Kawai H, Deguchi S, Yamashita T et al. Synergistic benefit of combined amlodipine plus atorvastatin on neuronal damage after stroke in Zucker metabolic rat 2011; 1368: 317–23.
13. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survial Study (4S). Lancet 1994, 344: 1383–9.
14. Heart Protection Study Collaborative Group MRS/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 23–4.
15. Schwartz GG, Olsson AG, Ezekowitz MD et al. Effects of Atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomised controlled trial. JAMA 2001; 285: 1711–8.
16. La Rosa JC, Grundy, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425–35.
17. Greisenegger S, Mullner M, Tentschert S et al. Effect of pretreatment with statins on the severity of acute ischemic cerebrovascular events. J Neurol Sci 2004; p. 5–10
18. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs 2004; 64 (Suppl. 2): 43–60.
19. Всероссийское научное общество кардиологов (ВНОК), Национальное общество по изучению атеросклероза (НОА), Российское общество кардиосоматической реабилитации и вторичной профилактики (РОСОКР). Заключение экспертов по оптимизации терапии статинами в клинической практике. Рациональная фармакотерапия в кардиологии. 2011; 7 (1): 107–9.
20. Takemoto M, Node K, Nakagami H et al Statins as antioxidant therapy for preventing cardiac myocyte hypertropty. J Clin Invest 2001; 108 (10): 1429–37.
21. Fonarow GC, Right RS, Spencer FA et al. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol 2005; 96: 611–6.
22. Fruchart JC, Duriez P. HMG CoA reductase inhibitors and PPAR-alpha activators: are their effects on high-density lipoprotein cholesterol and their pleiotropic effects clinically relevant in prevention trials? Curr Atheroscler Rep 2002; (6): 403–4.
23. Оkazaki S, Yokoyama T et al. Early statin treatment in patients with acute coronary syndrome demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event the ESTABLISH Study Circulation 2004; 110 (9): 1061–8.
24. Horne BD, Muhlestein JB, Carlquist JF et al. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. J Am Coll Cardiol 2000; 36 (6): 1774–80.
25. De Sutter J, Kazmierczak J, Fonteyne W et al. Factors determining long term outcomes and survival in patients with coronary artery disease and ventricular tachyarrhythmias: a single center experience. Pacing Clin Electrophysiol 2000; 23 (11 Pt. 2): 1947–52.
26. Lorenz H, Junger C, Seidl K et al. Do statin influence the prognostic impact of non- sustained ventricular tachycardia after ST-elevation myocardial infarction? Eur Heart J 2005; 26: 1078–85.
27. Patti G, Chello M, Candura D et al. Randomised Trial of Atorvastatin for Reduction of Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery. Circulation 2006; 114: 1455–6128.
28. Tang Q, Huang J, Qian H et al. Antiarrhythmic effect of atorvastatin on autoimmune myocarditis is mediated by improving myocardial repolarization. Life Sci 2007; 80 (7): 601–8.
29. Kumagai K, Nakashima H, Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibition in a canine sterile pericarditis model. Cardiovasc Research 2004, 62: 105–11.
30. Pasceri V, Patti G, Nusca A et al. Randomised Trial of Atorvastatin for Reduction of Myocardial Damage During Coronary Intervention. Circulation 2004; 110: 674–8.
31. Rikitake Y, Kawashima S et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterolfed rabbits Atherosclerosis 2001; 154 (1): 87–96.
32. Pehlivanidis AN, Athyros VG, Demitriadis DS et al. Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease. Atherosclerosis 2001; 157 (2): 463–9.
33.Young-Xu Y, Jabbour S et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003; 15, 92, 12: 1379–83.
Авторы
Д.М.Аронов, М.Г.Бубнова
ФГБУ Государственный научно-исследовательский центр профилактической медицины Минздрава РФ, Москва
State Research Center of Preventive Medicine, Ministry of Health of the Russian Federation, Moscow
ФГБУ Государственный научно-исследовательский центр профилактической медицины Минздрава РФ, Москва
________________________________________________
State Research Center of Preventive Medicine, Ministry of Health of the Russian Federation, Moscow
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.